JP2022548364A5 - - Google Patents
Info
- Publication number
- JP2022548364A5 JP2022548364A5 JP2022516618A JP2022516618A JP2022548364A5 JP 2022548364 A5 JP2022548364 A5 JP 2022548364A5 JP 2022516618 A JP2022516618 A JP 2022516618A JP 2022516618 A JP2022516618 A JP 2022516618A JP 2022548364 A5 JP2022548364 A5 JP 2022548364A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- fusion protein
- cancer
- variant
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19198358.4A EP3795583A1 (en) | 2019-09-19 | 2019-09-19 | Il10/fc fusion proteins useful as enhancers of immunotherapies |
| EP19198358.4 | 2019-09-19 | ||
| PCT/EP2020/076089 WO2021053134A1 (en) | 2019-09-19 | 2020-09-18 | Il-10/fc fusion proteins useful as enhancers of immunotherapies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548364A JP2022548364A (ja) | 2022-11-18 |
| JP2022548364A5 true JP2022548364A5 (https=) | 2023-09-11 |
| JP7822620B2 JP7822620B2 (ja) | 2026-03-03 |
Family
ID=68069476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516618A Active JP7822620B2 (ja) | 2019-09-19 | 2020-09-18 | 免疫療法のエンハンサーとして有用なｉｌ－１０／ｆｃ融合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220370564A1 (https=) |
| EP (2) | EP3795583A1 (https=) |
| JP (1) | JP7822620B2 (https=) |
| KR (1) | KR20220065839A (https=) |
| CN (1) | CN114728041A (https=) |
| AU (1) | AU2020351062B2 (https=) |
| BR (1) | BR112022005159A2 (https=) |
| CA (1) | CA3150050A1 (https=) |
| MX (1) | MX2022003417A (https=) |
| WO (1) | WO2021053134A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021231447A1 (en) * | 2020-05-12 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Novel il10 agonists and methods of use thereof |
| WO2022038298A1 (en) * | 2020-08-21 | 2022-02-24 | Université de Lausanne | Mpc inhibition for producing t-cells with a memory phenotype |
| EP4285913A1 (en) * | 2022-05-30 | 2023-12-06 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Highly effective adoptive t cell therapy |
| EP4719458A2 (en) * | 2023-06-01 | 2026-04-08 | Synthekine, Inc. | Il10 inverted monomers |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| WO2011064758A2 (en) * | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| HUE030100T2 (en) * | 2010-02-19 | 2017-04-28 | Xencor Inc | New CTLA4-IG immunoadhesins |
| CN101948543B (zh) | 2010-08-30 | 2013-01-16 | 中国科学技术大学 | 一种融合蛋白及其编码基因与应用 |
| AU2012275295B2 (en) | 2011-06-28 | 2016-11-10 | Inhibrx, Lp | WAP domain fusion polypeptides and methods of use thereof |
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| AU2015364396B2 (en) | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| WO2017087784A1 (en) * | 2015-11-18 | 2017-05-26 | Duke University | Tumor infiltrating lymphocytes for treatment of cancer |
| WO2018005226A2 (en) * | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| CN106317226B (zh) | 2016-08-19 | 2017-09-05 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| WO2018067993A1 (en) * | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| CN108948207B (zh) | 2017-05-22 | 2020-11-13 | 杭州博虎生物科技有限公司 | 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用 |
| JP2020530280A (ja) | 2017-07-03 | 2020-10-22 | トルク セラピューティクス， インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
| CN111094356B (zh) * | 2017-09-25 | 2022-11-01 | 苏州丁孚靶点生物技术有限公司 | 一种蛋白质异二聚体及其用途 |
-
2019
- 2019-09-19 EP EP19198358.4A patent/EP3795583A1/en not_active Withdrawn
-
2020
- 2020-09-18 US US17/760,947 patent/US20220370564A1/en active Pending
- 2020-09-18 WO PCT/EP2020/076089 patent/WO2021053134A1/en not_active Ceased
- 2020-09-18 CN CN202080076692.1A patent/CN114728041A/zh active Pending
- 2020-09-18 JP JP2022516618A patent/JP7822620B2/ja active Active
- 2020-09-18 EP EP20771582.2A patent/EP4031564A1/en active Pending
- 2020-09-18 MX MX2022003417A patent/MX2022003417A/es unknown
- 2020-09-18 BR BR112022005159A patent/BR112022005159A2/pt unknown
- 2020-09-18 KR KR1020227013049A patent/KR20220065839A/ko active Pending
- 2020-09-18 CA CA3150050A patent/CA3150050A1/en active Pending
- 2020-09-18 AU AU2020351062A patent/AU2020351062B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548364A5 (https=) | ||
| JP2023123502A5 (https=) | ||
| JP2023506454A5 (https=) | ||
| JP2021113191A (ja) | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 | |
| JP2019523630A5 (https=) | ||
| CN117042806A (zh) | 抗体-免疫激动剂缀合物及其应用 | |
| JP2024500847A5 (https=) | ||
| JP2021521822A5 (https=) | ||
| JP2019531728A5 (https=) | ||
| JP2020529864A5 (https=) | ||
| TW201609152A (zh) | 包含細胞結合劑及細胞毒性劑之偶聯物 | |
| JP2025508009A5 (https=) | ||
| Mahmoudi et al. | Recombinant immunotoxins development for HER2-based targeted cancer therapies | |
| JP2016519651A5 (https=) | ||
| WO2018127175A1 (zh) | 抗5t4抗体-药物偶联物及其应用 | |
| CN117946277A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP7811217B2 (ja) | 抗ｈｅｒ２抗体－免疫アゴニストコンジュゲート及びその使用 | |
| CA2560278A1 (en) | Modified bouganin proteins, cytotoxins and methods and uses thereof | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| KR20240082324A (ko) | 면역 관문 분자와 결합 가능한 분자가 융합된 단백질 및 이의 용도 | |
| Schaedel et al. | Antibodies and their fragments as anti-cancer agents | |
| JP2024543043A5 (https=) | ||
| Roshan et al. | A novel immunotoxin targeting epithelial cell adhesion molecule using single domain antibody fused to diphtheria toxin | |
| Accardi et al. | Antibodies in single-chain format against tumour-associated antigens: present and future applications | |
| CN115052663A (zh) | Alk5抑制剂缀合物及其用途 |